Cellectis SA

ALCLS

Company Profile

  • Business description

    Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

  • Contact

    8, rue de la Croix Jarry
    Paris75013
    FRA

    T: +33 181691600

    https://www.cellectis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    222

Stocks News & Analysis

stocks

Here’s how to value a share

Our best resources to help investors determine the value of a share.
stocks

How to avoid dividend disaster

Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks

GyG punished by market after solid earnings

Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,256.8054.50-0.59%
CAC 407,969.6931.400.40%
DAX 4024,363.0969.750.29%
Dow JONES (US)45,631.74846.241.89%
FTSE 1009,321.4012.200.13%
HKSE25,840.06500.921.98%
NASDAQ21,496.54396.221.88%
Nikkei 22542,922.04288.750.68%
NZX 50 Index13,102.1759.410.46%
S&P 5006,466.9196.741.52%
S&P/ASX 2008,984.4059.70-0.66%
SSE Composite Index3,866.8941.131.08%

Market Movers